← Back to Search

Unknown

DZD9008 and carbamazepine for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Dizal Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

This trial studies how two medications, itraconazole and carbamazepine, affect the processing of another drug, DZD9008, in healthy adults. Itraconazole slows down drug breakdown, while carbamazepine speeds it up. The goal is to understand how these changes impact DZD9008. Carbamazepine is a well-established medication used primarily to treat epilepsy and has been studied extensively for its effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: DZD9008 and itraconazoleExperimental Treatment1 Intervention
Subjects in arm 1 will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
Group II: DZD9008 and carbamazepineExperimental Treatment1 Intervention
Subjects in arm 2 will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Itraconazole
FDA approved
Carbamazepine
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Dizal PharmaceuticalsLead Sponsor
24 Previous Clinical Trials
2,834 Total Patients Enrolled
Tianwei ZhangStudy DirectorDizal Pharma
1 Previous Clinical Trials
230 Total Patients Enrolled
~11 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top